This Under-the-Radar Healthcare Company Quietly Surged During the Pandemic
The leader in organ transplant diagnostics, CareDx (NASDAQ:CDNA), reported record first-quarter earnings on Wednesday. Total revenue was up 76% year over year to $67.4 million, a rise of 15% sequentially. Notably, that growth was not coming off a pandemic-induced sales lull; the company reported 51% revenue growth in 2020. Sales of CareDxs blood test for detecting injuries to a transplanted heart or kidney increased 89% year over year to $59.3 million in Q1. The company provided about 33,000 ...
Source: fool.com